Hope for takayasu patients: study tests stopping biologic drugs after years of remission
NCT ID NCT07491913
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether people with Takayasu arteritis, a rare blood vessel disease, can safely stop taking biologic medications after being in remission for a long time. About 40 participants who have been on biologics for at least 3 years and have no active disease will slowly reduce their dose over 3 months and then stop. They will be monitored for 12 months to see if the disease stays under control without medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TAKAYASU ARTERITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Marmara University Pendik Training and Research Hospital
RECRUITINGIstanbul, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Rare artery disease linked to higher heart attack and stroke risk
- New Total-Body PET scanner could revolutionize vasculitis diagnosis
- 5,000 patients to help unlock secrets of inflammatory heart disease
- New hope for rare artery disease? small trial tests upadacitinib
- New drug aims to tame rare artery disease